FR0005175080
© Globe Newswire
12.01.2026
TNG
LISTED
EURONEXT
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2025
News Preview
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA
as of December 31, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.01.2026
TNG
LISTED
EURONEXT
Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse
News Preview
Transgene Publishes Phase I Data Supporting TG4050’s Potential
in Preventing Head and Neck Cancer Relapse...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
TNG
LISTED
EURONEXT
Transgene to Participate in Upcoming Investor Meetings
News Preview
Strasbourg (France), December 17, 2025, 17:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors during the upcoming editions of:...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
26.11.2025
TNG
LISTED
EURONEXT
Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets
News Preview
Strasbourg, France, 27 November 2025, 00:15 a.m. CET – Transgene (Euronext Paris: TNG) had requested the suspension of trading of its shares (ISIN: FR0005175080) on Euronext Paris as from Wednesday, 26 November 2025, before market opening, pending the publication of the results of its capital increase....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
26.11.2025
TNG
LISTED
EURONEXT
Transgene Successfully Completes a Fundraising of c. €105 Million
News Preview
This press release may not be distributed directly or indirectly in the United States, Canada, United Kingdom, Australia or Japan....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2025
TNG
LISTED
EURONEXT
Correction: Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris
News Preview
Strasbourg, France, November 25, 2025, 7:45 p.m. CET – Transgene (Euronext Paris: TNG) has requested Euronext Paris to suspend trading of its shares (ISIN: FR0005175080) as of Wednesday, November 26, 2025, before the markets open, pending the publication of the results of its capital increase....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2025
TNG
LISTED
EURONEXT
Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris
News Preview
Strasbourg, France, November 25, 2025, 7:45 p.m. CET – Transgene (Euronext Paris: TNG) has requested Euronext Paris to suspend trading of its shares (ISIN: FR0005175080) as of Wednesday, November 26, 2025, before the markets open, pending the publication of the results of its capital increase....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2025
TNG
LISTED
EURONEXT
Correction: Transgene launches a fundraising campaign for approximately 105 million euros
News Preview
This press release may not be distributed directly or indirectly in the United States, the United Kingdom, Canada, Australia, or Japan. ...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2025
TNG
LISTED
EURONEXT
Transgene launches a fundraising campaign for approximately 105 million euros
News Preview
This press release may not be distributed directly or indirectly in the United States, the United Kingdom, Canada, Australia, or Japan....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
TNG
LISTED
EURONEXT
Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
News Preview
Computational tool improves recombinant virus design efficiency and yield....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
TNG
LISTED
EURONEXT
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
News Preview
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
TNG
LISTED
EURONEXT
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
News Preview
Poster presentation on BT-001 in combination with pembrolizumab has shown tumor shrinkage in both injected and non-injected lesions...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
03.10.2025
TNG
LISTED
EURONEXT
Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025
News Preview
Strasbourg, France, October 3, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting in-depth analysis of the neoantigen-specific T cell response from the randomized Phase I trial of its individualized therapeuti...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
TNG
LISTED
EURONEXT
Availability of Transgene’s Half-Year Financial Report as of June 30, 2025
News Preview
TRANSGENE (Paris: TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
TNG
LISTED
EURONEXT
2025 Half-year financial information
News Preview
2025 Half-year financial information...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
TNG
LISTED
EURONEXT
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data Randomization to be Completed in Phase II Part in Q4 2025
News Preview
2025 Half-Year Results and Business Update...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.07.2025
TNG
LISTED
EURONEXT
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001, at ESMO 2025
News Preview
Poster presentation of updated data on BT-001 from the Phase I part of the ongoing Phase I/IIa study in solid tumors...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2025
TNG
LISTED
EURONEXT
Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independent Director
News Preview
Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors. She succeeds Philippe Archinard, who is retiring from the B...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.07.2025
TNG
LISTED
EURONEXT
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2025
News Preview
Strasbourg, July 8, 2025 – 06:00 pm CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.06.2025
TNG
LISTED
EURONEXT
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer
News Preview
Phase I part showed 100% Disease-Free Survival (DFS) after a minimum of 2-year follow-up – providing clinical proof of principle for TG4050...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.06.2025
TNG
LISTED
EURONEXT
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
News Preview
Strasbourg (France), June 13, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors, scientists and leaders of the biotechnology ecosystem during the upcoming editions of:...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2025
TNG
LISTED
EURONEXT
Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025
News Preview
Strasbourg (France), June 3, 2025, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced it will host a live webcast to discuss the latest positive clinical data from its individualized neoantigen cancer vaccine, TG4050, presented at the...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.06.2025
TNG
LISTED
EURONEXT
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050
News Preview
All patients in the treatment arm remain disease-free after a minimum of 2-year follow-up in the randomized Phase I trial in resected HPV-negative locally advanced head and neck cancer – Demonstrating clinical proof of principle for TG4050...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2025
TNG
LISTED
EURONEXT
Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
News Preview
24-month follow-up data from randomized Phase I part of the Phase I/II trial of TG4050 in resected locally advanced head and neck cancer selected for rapid oral presentationat ASCO on June 1st, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.04.2025
TNG
LISTED
EURONEXT
Transgene Provides Business and Financial Update for Q1 2025
News Preview
TG4050: Updated randomized Phase I data to be presented in Rapid Oral Presentation at ASCO 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.04.2025
TNG
LISTED
EURONEXT
Availability of Preparatory Documents for the Combined General Meeting of May 15, 2025
News Preview
Strasbourg, France, April 24, 2025, 8:00 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shareholders is available....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.04.2025
TNG
LISTED
EURONEXT
Availability of Transgene’s 2024 Universal Registration Document (URD)
News Preview
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2024 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 10, 2025, under number D.25-0243....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.04.2025
TNG
LISTED
EURONEXT
Document d'Enregistrement Universel 2024
News Preview
Document d'Enregistrement Universel 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.03.2025
TNG
LISTED
EURONEXT
Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ̶ Strong Outlook for 2025
News Preview
2024 Full-year results and business update...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.01.2025
TNG
LISTED
EURONEXT
Transgene to Participate in the Biomed Forum Investor Conference
News Preview
Strasbourg (France), January 21, 2025, 5:45 PM CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors. Organized by AllIn...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2025
TNG
LISTED
EURONEXT
Transgene Announces Financial Calendar for 2025
News Preview
Strasbourg (France), January 14, 2025, 5:45 p.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces its financial reporting dates for 2025:...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2024
TNG
LISTED
EURONEXT
Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
News Preview
Transgene will present median 24-month follow up data from patients enrolled in the Phase I trial evaluating the individualized cancer vaccine TG4050 in the adjuvant treatment of head and neck cancer...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2024
TNG
LISTED
EURONEXT
2024 Half-Year Financial Report
News Preview
2024 Half Year Financial Report...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2024
TNG
LISTED
EURONEXT
Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
News Preview
2024 Half-Year Results and Business Update...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2024
TNG
LISTED
EURONEXT
Availability of Transgene’s Half-Year Financial Report as of June 30, 2024
News Preview
TRANSGENE (Paris: TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.09.2024
TNG
LISTED
EURONEXT
Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
News Preview
Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.09.2024
TNG
LISTED
EURONEXT
Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
News Preview
BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2024
TNG
LISTED
EURONEXT
Transgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 published in JITC
News Preview
These data, published in The Journal for ImmunoTherapy of Cancer (JITC), demonstrate that TG6050 induces tumor regression and profound remodeling of the tumor microenvironment...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2024
TNG
LISTED
EURONEXT
Transgene annonce la mise à disposition d’un prospectus dans le cadre de la conversion en actions d’une partie de l’avance en compte-courant de TSGH
News Preview
Ce communiqué ne peut être publié, transmis ou diffusé ou distribué, directement ou indirectement, aux États-Unis, au Canada, en Australie ou au Japon....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2024
TNG
LISTED
EURONEXT
Transgene renforce son bilan par la conversion en actions d’une partie de l’avance en compte-courant de TSGH
News Preview
Ce communiqué ne peut être publié, transmis ou diffusé ou distribué, directement ou indirectement, aux États-Unis, au Canada, en Australie ou au Japon....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.07.2024
TNG
LISTED
EURONEXT
Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
News Preview
Strasbourg, France, and Lund, Sweden, July 22, 2024, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and firs...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.07.2024
TNG
LISTED
EURONEXT
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2024
News Preview
Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of June 30, 2024, the following resources were managed through the liquidity account:...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
